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Despite remarkable therapeutic advances have been made in the last few decades, non-small cell lung cancer (NSCLC) is still one of
the leading causes of death worldwide. Brain metastases are a common complication of a wide range of human malignancies and in
particular NSCLC. Brain-derived neurotrophic factor (BDNF), binding its high-aﬃnity tyrosine kinase B receptor, has been shown
to promote cancer progression and metastasis. We hereby investigated the expression of the BDNF and its TrkB receptor in its fulllength and truncated isoform T1, in samples from primary adenocarcinomas (ADKs) of the lung and in their metastasis to evaluate
if their expression was related to preferential tumor entry into the central nervous system (CNS). By immunohistochemistry, 80% of
the ADKs that metastasize to central nervous system expressed TrkB receptor compared to 33% expressing of ADKs without CNS
metastasis. Moreover, ADKs with CNS metastasis showed an elevated expression of the full-length TrkB receptor. The TrkB
receptor FL/T1 ratio was statistically higher in primary ADKs with brain metastasis compared to ADKs without brain
metastasis. Our data indicate that TrkB full-length isoform expression in primary ADK cells may be associated with higher risk
to develop brain metastasis. Therefore, TrkB receptor may possess prognostic and therapeutic implications in lung ADK.

1. Introduction
NSCLC is an aggressive malignancy with rapid progression
and low survival rate [1]. Although the advent of targeted
therapies has signiﬁcantly extended life expectancy, yet only
a small percentage of patients are currently eligible. The
majority of the advances have been made for the treatment
of lung adenocarcinomas (ADKs) which represent the
majority of the NSCLC, and that is characterized by considerable molecular heterogeneity [2]. In this regard, diﬀerent
molecular aberrations including EGFR, ALK, and ROS1
mutation have proved to be eﬀective therapeutic targets [3].
Unfortunately, only less than 20% of ADK patients express

these sensible mutations, leaving the large majority of
NSCLC out of range for a targeted therapy. In addition to
that, patients inevitably acquire resistance to this form of
treatment over the time [4]. These observations highlight
the importance of improving the knowledge of NSCLC
molecular biology with the aim of developing novel molecular targets able to extend patient survival.
Neurotrophins (NTs) are a family of growth factors with
important pleiotropic function in the central and peripheral
nervous system [5]. NT family consists of principally four
peptides, the prototype nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), the NT 3, and the NT
4/5 [6]. All these growth factors bind to the low-aﬃnity pan
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NT P75 receptor [7]. Moreover, NTs bind speciﬁc highaﬃnity tropomyosin-related kinase (Trk) receptors. BDNF
preferentially binds the TrkB, a tyrosine kinase receptor
located at the cellular membrane whose intracellular signaling is implicated in neuronal survival and diﬀerentiation.
The BDNF/TRKB axis has been shown to be activated in
several human malignancies [8, 9] with important eﬀect on
cancer cells behavior [10]. In particular, TrkB expression on
cancer cells has been associated with aggressiveness and tendency to metastasize [11]. TrkB activate may be expressed in
a number of diﬀerent isoforms [12]. Biological activity
required the TrkB full-length isoform (TrkB-FL). The functions of the truncated isoforms (TrkB-T1 and TrkB-T2) are
unclear although under some conditions can function as
dominant negatives [13]. In addition, the release of BDNF
from cancer cells may also be involved in that cross talk
between stroma and cancer, facilitating a microenvironment
favorable for cancer metastasis. It is well known that microenvironment may be essential for cancer cell survival and
development. Based on the well-known neurotrophic function displayed by the BDNF/TRKB axis within the nervous
system, we hypothesize that the expression of the TRKB
receptors and/or the release of neurotrophic growth factors
may allow ADK cells to survive and proliferate in a so speciﬁc
microenvironment [9]. Furthermore, we have also investigated the possible role of TrkB isoforms to contribute to this
phenomenon. Therefore, the aim of the present study has
been to demonstrate if TrkB isoforms and BDNF expression
in primary ADKs of the lung may be associated with increasing risk to develop metastasis to the brain.

2. Materials and Methods
2.1. Patients. We collected a total of 55 tissue samples
obtained from patients who underwent surgical lung resection or lung biopsies at Sant’Andrea Hospital between 2007
and 2019. All patients had a diagnosis of primary ADK on
the histological tissue examination. They were followed
clinically and radiologically, for almost two years from the
moment of diagnosis. None of them had received treatment
or had previous cancer history before lung surgery.
Group 1 was represented by 20 tissue lung samples of
patients with brain metastasis. Among them, only 10 patients
staged as stages II and IIIa, who underwent lung cancer resection, developed brain solitary metastasis during the follow-up
that was treated surgically. Therefore, for these patients, we
had the opportunity to process both primitive tumor and the
corresponding cerebral metastasis samples. In the same Group
1, we enrolled 10 no resectable ADKs (stages III and IV) with
brain metastasis of which we studied the lung cancer specimens.
Group 2 was represented by 15 patients aﬀected with ADK
of the lung stages IIIb and IV who did not develop brain metastasis during their follow-up. Samples from these patients were
derived from surgical biopsies. These patients were treated with
chemotherapy or, in selected cases, by TK inhibitors.
Group 3 was represented by 20 patients aﬀected by ADK
of the lung (stages IIIb and IV) with single or polymetastatic
disease in site diﬀerent from the brain. In this group, both
lung cancer and metastatic specimens were obtained.
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All the samples of each group were processed for TrkB
and BDNF immunohistochemical determination.
All patient’s characteristics are summarized in Table 1.
The study was approved by the Ethics Committee
(protocol number 1032/17).
2.2. Cancer Cell Cultures. Established human NSCLC cell line
NCI-H460 was used to better clarify the results obtained in
human cancer tissues. Cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA)
and was cultured according to the manufacturer’s instructions. The cancer cell line H460 was used and grown under
aseptic conditions as previously detailed [14]. Brieﬂy, the
cells were suspended in RPMI 1640 supplemented with
0.1% bovine serum albumin, 0.5 mg/ml fungizone, 5 mg/ml
gentamycin, 5 mM ethanolamine, 10 mM HEPES, 5 mg/ml
transferrin, 10 mM T3, 50 mM selenium, 5 mg/ml insulin,
and 1 mg/ml hydrocortisone. The cells were cultured at
37°C in culture ﬂasks. All cell culture reagents were obtained
from Sigma Chemical Co. (St. Louis, MO).
Cells were grown in adherence (ACC) and in spheroid
conditions. To generate spheres, cancer cells were suspended
in a Dulbecco’s modiﬁed Eagle’s medium/F12 (Invitrogen
Ltd.) supplemented with 50 ng/ml of epidermal growth factor
and 25 ng/ml of bovin fetal growth factor. Spheres were
observed using a microscope Zeiss Axiovert 25, Jena, Germany. After checking for single cells, the cells were pelleted
and suspended in sphere culture medium before replating
in nonadherent ﬂasks. In these conditions, cancer cells developed high expression of cancer stem cell-associated markers
(CSC) (data not shown).
2.3. RNA Extraction, Reverse Transcription, and PCR. The
expression of full-length TRKB, TRKB-T1, in lung tissues
was studied by evaluating RNA levels. RNA from surgical
and biopsy-derived samples was collected from ﬁve 5 μm
thick sections of tissue mounted on a microscopic slide.
The slides were stained in hematoxylin and eosin and evaluated by the pathologist to select areas richer in tumor cells.
Total RNA was obtained using the High Pure FFPE RNA
Micro KIT (Roche Diagnostics, Germany), an isolation kit
designed to extract all nucleic acids (RNA, miRNA, and
DNA) from formalin-ﬁxed and paraﬃn-embedded tissues.
TRIzol, phenol, and chloroform were used for RNA extraction from cell lines. RNA integrity was evaluated by agarose
gel electrophoresis and spectrophotometry. Four micrograms
of total RNA extracted from tissue was reverse transcribed in
a ﬁnal volume of 20 μL using the Fast Gene Scriptase II kit
(LS63, NIPPON Genetics Europe, RESNOVA, Italy). The
cDNA was at -20°C until further analysis. A positive control
also used cDNA obtained from RNA extracted from a sample
of diﬀused cerebral neoplasia. The genes of interest were
evaluated by PCR analysis using the following speciﬁc
primers: TRKB FL forward 5- TAC ATC TGT ACT AAA
ATACA-3, reverse 5- GTG TCC CCG ATG TCA TTC GC
-3, TRKB T1 forward 5- TAA AAC CGG TCG GGA ACA
TC -3 reverse 5- ACC CAT CCA GTG GGA TCT TA -3,
and BDNF forward 5- AAC AAT AAG GAC GAC GAC
TT -3 reverse 5- TGC AGT CTT TTT GTC TGC CG -3. In
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Table 1: Demographic and clinical characteristics of patients studied.
Patients

Group 1 (n = 20)

Group 2 (n = 15)

Group 3 (n = 20)

Age

62:90 + 7:6

73 + 4:2

61 + 15:75

Gender (F/M)

6/14
II-III: 10
IIIb, IV: 10
20
10
nd

11/9
III: 8
IV: 7
15
nd
nd

12/8
III: 12
IV: 8
20
nd
20

Stage at diagnosis
Lung cancer (ADKs)
Brain metastasis
Bone (2), skin (5), and liver (13) metastases
nd: not detected.

order to normalize the amount of total cDNA present in each
reaction, the B-actin gene was ampliﬁed.
2.4. Quantitative Real-Time PCR (qRT PCR). The expression
of full-length TRKB, TRKB T1, in the lung tissues of metastatic and not metastatic patients was studied by evaluating
RNA levels using a SYBR Green real-time PCR assay using
the following speciﬁc primers: TRKB FL forward 5- GGCC
CAGATGCTGTCATTAT-3 reverse 5-TCCTGCTCAGG
ACAGAGGTT-3; TRKB-T1 forward 5-ATCCCTTCCAC
AGACGTCAC-3 reverse 5- CCATCCAGTGGGATCTTAT
GAAAC-3; and BDNF forward 5- AACAATAAGGACGC
AGACTT-3 reverse 5-TGCAGTCTTTTTGTCTGCCG-3.
To normalize the total amount of cDNA present in each reaction, the β-actin gene was ampliﬁed: actin forward 5- CGGT
TCCGCTGCCCTGAG-3 reverse 5- TGGAGTTGAAGGTA
GTTTCGTGGAT-3. The data have been expressed as relative units (UR) to control.
Levels of full-length TRKB, TRKB-T1, and BDNF were
also measured from 2 stable cell lines derived from lung
adenocarcinoma (WT 02/19/18, SPHER-MEP 02/21/18)
which diﬀered in the type of growth, adherent or spheroidal.
2.5. Immunohistochemistry. Histological sections ﬁxed in
formalin and included in paraﬃn were immunostained with
the following antibodies: rabbit anti-human TrkB antibody
(sc-12 rabbit polyclonal aﬃnity puriﬁed antibody raised
against a peptide mapping within the C-terminal cytoplasmic
domain of TrkB of mouse origin, Santa Cruz Biotechnology,
Dallas, Texas USA) dilution 1 : 500; rabbit anti-human
-BDNF polyclonal antibody (H20, sc-548; epitope mapping
at the N-terminus of the mature chain of mature NGF of
human origin, Santa Cruz Biotechnology, Dallas, Texas
USA) dilution 1 : 1000 dilution. After incubation, slides were
exposed to anti-rabbit secondary antibody (1 : 100). The
product of immune reaction was revealed using the three
steps labeled the streptavidin–biotin–immunoperoxidase
technique (LSAB2, DAKO, Glostrup, Denmark). The
sections were then washed, dehydrated, mounted, and
viewed under a light microscope. The analysis of the results
was independently performed by two expert pathologists.
The staining was evaluated as percentage of positive cells.
Cases with more than 5% positive cancer cells were classiﬁed
as positive. Cases with less than 5% of positive cancer cells
were considered negative. The immunohistochemical expres-

sion of the TRKB and BDNF protein was also evaluated as
color intensity (1, low intensity; 2, medium intensity; and 3,
high intensity). No speciﬁc binding was obtained by antibodies preabsorbed with the corresponding blocking peptides
(10 μg/ml).
2.6. Statistics. Data were expressed as mean ± standard
deviation (SD). The chi-square test or Fisher’s exact test
was used for categorical data, and Student’s t-test was used
for continuous data. Statistical analysis was performed by
using GraphPad, and a p value < 0.05 was considered significant. All in vitro experiments were performed in triplicate.

3. Results
3.1. Immunohistochemical Expression of TrkB and BDNF.
The expression of TrkB was demonstrated by immunohistochemistry (IHC). The expression of TrkB was detected in
paraﬃn-embedded section obtained from samples of lung
cancer and brain, skin, bone, and liver metastases. The reaction product was visualized in brown in tumor immunopositive cells, within the cytoplasm. The results showed a
statistically signiﬁcant diﬀerence, in the TrkB receptor
immunohistochemical expression, in tissue samples obtained
from ADKs of the lung obtained from patients belonging to
Group 1 (lung cancer with brain metastasis) and Group 2
(lung cancer without brain metastasis) (1:9 ± 1:1 and 0:7 ±
0:9, respectively) expressed in arbitrary unit (p = 0:017)
(Figure 1). On the contrary, the expression of BDNF is higher
in the Group 2 (1:33 ± 0:5 in Group 1; 1:88 ± 1:3 in Group 2)
(p = 0:26) (Figure 1). The number of patients that expressed
TrkB in medium-high intensity in Group 1 versus Group 2
was, respectively, 16/20 (80%) and 5/15 (33%) (Figure 2).
TrkB and BDNF were also demonstrated by IHC in
patients belonging to Group 1 in both lung cancer and the
corresponding brain metastasis. The expression of TrkB
was higher in brain metastasis than corresponding primitive
lung cancer (2:8 ± 0:4 vs. 1:9 ± 1:1) (p = 0:02) (Figure 3).
Similarly, BDNF was more expressed in metastasis than in
the corresponding primitive lung cancer from which they
originated (2:2 ± 0:6 vs. 1:3 ± 0:5) (p = 0:004) (Figure 3).
Finally, the expression of TrkB and BDNF was estimated
on sample tissue obtained from metastasis of lung cancer
diﬀerent from brain, in particular, liver (n = 13), bone
(n = 2), and skin (n = 5) (Figure 4). In these samples, BDNF
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Figure 1: Immunohistochemical detection of TrkB and BDNF protein expression in sections of primitive ADKs of the lung with (Group 1) or
without (Group 2) brain metastasis. The histograms summarize the results obtained. A statistically signiﬁcant increase of TrkB protein
expression was observed in samples from primitive ADK in Group 1 compared with Group 2. The BDNF protein expression was higher
in Group 2 in comparison with Group 1. Notice the anatomical localization of BDNF and TrkB protein expression in ADK cell. BDNF
antibodies generated a prevalent nuclear dark brown immunoreaction. The TrkB antibody generated a cytoplasmic and cell membrane
immunoreaction. A clear and speciﬁc TrkB and BDNF immunostaining was documented in ADKs cells in both primitive and brain
metastasis in Group 1. Contrarily, in Group 2, a strong and speciﬁc BDNF immunostaining was documented in brain metastasis, but not
for TrkB. The data are the mean + SD of diﬀerent experiments performed in triplicate. ×20 ∗p < 0:0177.

of PCR process. Thus, we demonstrated the expression of
the full-length (FL) TrkB receptor and truncated (T1)
isoforms. The expression of the FL is higher in Group 1 compared to Group 2 (1:025 ± 0:68 and 0:5 ± 0:96, respectively).
Contrarily, the T1 isoform was more expressed in Group 2
(Figure 5). Interestingly, the FL/T1 ratio conﬁrmed this
behavior, showing that patients belonging to the Group 1
had a statistically higher ratio in comparison with Group 2
(6:59 ± 7:10 vs. 0:48 ± 0:94) (p = 0:014) (Figure 5).

80

Patients (%)

60
40
20
0

0

1

2

3

TrkB IHC intensity
Group 1
Group 2

Figure 2: Distribution among the groups of TrkB intensity
immunostaining (0: expression < 5%; 1: low intensity; 2: moderate
intensity; and 3: high intensity) detected in sections of primitive
ADKs of the lung with (Group 1) and without (Group 2) brain
metastasis. The results are the mean of three independent expert
pathologist evaluation. ×20.

antibody generated a speciﬁc immunostaining in cancer cells
in the 75% of the samples. On the contrary, we detected a
speciﬁc TrkB immunostaining in only one sample of liver
metastasis.
3.2. Real-Time Quantitative Reverse Transcription PCR. Since
our immunohistochemical analysis was unable to discriminate which receptor isoform (full-length TRKB or TRKBT1) prompted us to identify the relative expression of the different isoforms by further and more sensitive investigation
techniques. qRT-PCR allows us to enable reliable detection
and measurement of products generated during each cycle

3.3. TrkB Receptor and BDNF in Primary Adherent and
Spheroid Cell Cultures. Spheroid cancer cell mimics the characteristics of cancer stem cells with migratory capacity and
resistance to chemotherapy resembling the “in vitro” counterpart of metastatic cells [15].
For this reason, we compared the TrkB and BDNF levels
in spheroid versus adherent cancer cells. Data obtained by
RT-PCR and qRT-PCR showed that the expression of both
isoforms was higher in cell grown in adherence. Moreover,
the FL/T1 ratio was higher in cell grown under spheroid conditions (1:07 ± 0:05 and 1:14 ± 0:02 in three independent
experiments) (p < 0:05) (Figure 6).

4. Discussion
Lung cancer is the leading cause of cancer-related death
worldwide. Brain metastasis occurs in almost 40% of NSCLC
patients [16] and is associated with a poor prognosis [17].
However, the factors that can favor brain metastasis in
NSCLC are still poorly understood. Here, we show that
patients aﬀected with ADK express higher levels of TrkB in
the presence of brain metastatic disease.
In the last few decades, it has become increasingly clear
that NTs and their TrkB receptors have a wide range of biological eﬀects in diﬀerent human malignancies [9, 18]. In the
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Figure 3: Immunohistochemical detection of TrkB and BDNF protein expression in section samples obtained by Group 1 (ADK with brain
metastasis). (a) The histograms summarize the results obtained. A statistical signiﬁcant increase of TrkB and BDNF protein expression was
observed in samples from metastasis compared with relative primitive ADKs. (b) Notice the anatomical localization of BDNF and TrkB
protein expression in ADK cells. A strong speciﬁc immunostaining was clearly documented in both primitive ADKs and brain metastasis
(a–d). The data are the mean ± SD of diﬀerent experiments performed in triplicate. ADK, primitive ADKs; BM, corresponding brain
metastasis. ∗p < 0:02; ∗∗p < 0:004.

BDNF IHC intensity
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Liver
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Figure 4: Immunohistochemical detection of BDNF protein expression in section of metastasis from the skin, liver, and bone. The BDNF
immunostaining was strongly expressed in the diﬀerent metastatic sites studied (a, b). Note the speciﬁc clear immunostaining within
cancer cells in metastatic cancer cells. ×20.
15

⁎

FL/T1

10

Group 2

BM

0

ADK

5

Figure 5: qRT-PCR. The histogram emphasizes the elevated TrkB
FL/T1 ratio in primary ADKs of the lung with brain metastasis.
The data are the mean ± SD of diﬀerent experiments performed in
triplicate. ADK, primitive ADKs; BM, corresponding brain
metastasis. ∗p < 0:01.

lung, NT and their high-aﬃnity receptors have been shown
to be present in tumor cells [18]. Moreover, the TrkB receptor expression has been often associated with unfavorable
prognosis [19]. Furthermore, we previously demonstrated
that TrkB expression in cancer cells promotes epithelial to
mesenchymal transition and that its inhibition results in a
less-aggressive phenotype [20]. Taken together, these observations point to TrkB/NT axis as a promising target for the
treatment of lung cancer.
TrkB possesses at least 3 splice variants: the catalytic tyrosine kinase receptor and two diﬀerent isoforms that lack the
intracellular kinase domain [21] named T1 and T2. Usually,
T1 and T2 receptors are able to attenuate or inhibit fulllength activation when coexpressed with the full length [22].
To this end, coexpression of BDNF and TrkB is often
responsive of poor prognosis and cancer progression and
migration in several tumor types [23]. Moreover, T1 expression in squamous cell lung carcinomas displayed better
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Figure 6: RT-PCR (a) and qRT-PCR (a) to clarify the FL TrkB and
TrkB-T1 isoform expression in lung adenocarcinoma cell lines
(NCI-H460) grown in adherence (AD) or in spheroid conditions
(SP). The total amount of cDNA present in each reaction was
normalized by β-actin gene ampliﬁcation. (a) The RT-PCR display
and increased expression of the FL/T1 ratio in spheroid cancer
cell. This data was conﬁrmed by qRT-PCR (b). AD, adherent cell
lines; SP, spheroid cell lines.

outcomes. Our data ﬁrstly show that ADKs with brain metastasis are more likely to express FL TrkB then the truncated
isoform. This data would conﬁrm the inhibitor role for
TrkB-T1 receptor, while the metastatic involvement of the
CNS appears to be a more frequent complication in patients
with the exclusive or prevalent full-length TrkB expression.
The TrkB FL/T1 ratio may be a potential feature to hypothesize the possible risk to develop CNS metastasis.
The BBB is a complex anatomical barrier, and the mechanism by which cancer cells pass through is still debated [22]. It
is in fact known that the blood brain barrier (BBB) remains
partially intact in experimental brain metastases [24]. Adhesion interaction between metastatic cancer cell and activated
endothelial cells mediated by integrins and vascular cell adhesion molecules (in particular VCAM-1) upon activation by
inﬂammatory stimuli may represent a key mechanism [22].
Our data show that BDNF levels are increased in ADK
with brain metastasis. Interestingly enough, BDNF has been
previously shown to be the ligand for the alpha9beta1
integrin whose activity could be related to its high crossreactivity with a variety of endogenous ligands such as
VCAM-1, tenascin C, and osteopontin [25–29]. The binding
of BDNF with this receptor displays complex proliferative
and migratory activity and may potentially promote migration through the BBB [30]. Moreover, among factors that
promote vascular proliferation and neoangiogenesis, BDNF
has been shown to increase VEGF release enhancing angiogenesis through a signal transduction pathway that involves
the TrkB receptor and the hypoxia-inducing factor- (HIF-)
1α expression [31].
Contrarily to primary cancer cells, in brain metastasis, we
have documented an increasing expression of BDNF, which
may be responsible for favoring cancer engraftment and
metastatic progression. It is known that disseminated cancer
cells derived from primary tumor, possessing a mesenchymal
phenotype, once engrafted into the brain, may undergo a
reverse process known as mesenchymal to epithelial transition; the transition actions for EMT and MET should be

critical to metastasis or demetastasis process [32]. This phenomenon may explain the diﬀerent TrkB receptor and BDNF
expression observed between primary and metastatic cancer
cells derived from the same patients. BDNF may be
extremely important for the survival of metastatic cancer
cells within the central nervous system. It is important to
underline that metastases into CNS are preferentially located
in the brain areas in which higher levels of BDNF are demonstrated. Interestingly, in our cases, brain metastases are
mainly located in the brain areas request in BDNF like frontal
and parietal cortexes [17].
Although our data are based on a small-case series, it may
stimulate further analysis for possible therapeutic application.

5. Conclusion
In ADKs of the lung, TrkB receptor expression in its FL isoform is often associated with metastatic brain disease. On the
contrary, the T1 truncated isoform share a protective role.
The TrkB FL/T1 ratio determinate in primary ADKs of the
lung may be considered a potential prognostic factor able to
predict the risk to develop CNS metastasis.
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